BACKGROUND AND PURPOSE: Poor treatment outcome remains high in patients with squamous cell carcinoma (SCC) of the head and neck region. Treatment of head and neck cancer could be improved and perhaps standardized if reliable markers for tumor progression and poor prognosis could be developed. MR spectroscopy has been used previously to differentiate between malignant and adjacent normal specimen in these cancers. This study explores the capability of MR spectroscopy in providing an indication of the aggressiveness of a tumor and its response to treatment. METHODS: Thirty-six SCC patients with treatment failure, and 22 other patients who were treated concurrently at the same center but with no indication of failure for a period of 3 years, were selected for the study. Tumor specimens were kept frozen at -70 degrees C, and later subjected to 1H-MR spectroscopy at 25 degrees C. The resonance areas for 6 spectral regions were determined, and their ratio calculated. The mean values of the ratios were then compared between the 2 groups by using the Student t test. RESULTS: The choline-to-creatine (3.2/3.0 parts per million [ppm]) and the 1.3/0.9 ppm spectral intensity ratios (signal due to lipid or lactic acid) were the 2 most notable ones to be significantly elevated in the group with poor response. Using these ratios, a sensitivity of 83% and a specificity of 82% were obtained in predicting which head and neck cancer patients would fail treatment. CONCLUSIONS: These preliminary results suggest that MR spectroscopy has the potential to contribute to an accurate and early prediction of tumor behavior and response to treatment in squamous cell carcinoma of the head and neck region.
BACKGROUND AND PURPOSE: Poor treatment outcome remains high in patients with squamous cell carcinoma (SCC) of the head and neck region. Treatment of head and neck cancer could be improved and perhaps standardized if reliable markers for tumor progression and poor prognosis could be developed. MR spectroscopy has been used previously to differentiate between malignant and adjacent normal specimen in these cancers. This study explores the capability of MR spectroscopy in providing an indication of the aggressiveness of a tumor and its response to treatment. METHODS: Thirty-six SCC patients with treatment failure, and 22 other patients who were treated concurrently at the same center but with no indication of failure for a period of 3 years, were selected for the study. Tumor specimens were kept frozen at -70 degrees C, and later subjected to 1H-MR spectroscopy at 25 degrees C. The resonance areas for 6 spectral regions were determined, and their ratio calculated. The mean values of the ratios were then compared between the 2 groups by using the Student t test. RESULTS: The choline-to-creatine (3.2/3.0 parts per million [ppm]) and the 1.3/0.9 ppm spectral intensity ratios (signal due to lipid or lactic acid) were the 2 most notable ones to be significantly elevated in the group with poor response. Using these ratios, a sensitivity of 83% and a specificity of 82% were obtained in predicting which head and neck cancerpatients would fail treatment. CONCLUSIONS: These preliminary results suggest that MR spectroscopy has the potential to contribute to an accurate and early prediction of tumor behavior and response to treatment in squamous cell carcinoma of the head and neck region.
Authors: D M Brizel; T Schroeder; R L Scher; S Walenta; R W Clough; M W Dewhirst; W Mueller-Klieser Journal: Int J Radiat Oncol Biol Phys Date: 2001-10-01 Impact factor: 7.038
Authors: S R Maheshwari; S K Mukherji; B Neelon; S Schiro; G M Fatterpekar; J A Stone; M Castillo Journal: AJNR Am J Neuroradiol Date: 2000 Nov-Dec Impact factor: 3.825
Authors: W B Mackinnon; P A Barry; P L Malycha; D J Gillett; P Russell; C L Lean; S T Doran; B H Barraclough; M Bilous; C E Mountford Journal: Radiology Date: 1997-09 Impact factor: 11.105
Authors: C E Mountford; R L Somorjai; P Malycha; L Gluch; C Lean; P Russell; B Barraclough; D Gillett; U Himmelreich; B Dolenko; A E Nikulin; I C Smith Journal: Br J Surg Date: 2001-09 Impact factor: 6.939
Authors: Ralf Kurek; Anna Kalogera-Fountzila; Klaus Muskalla; Urania Dafni; Thomas Schnabel; Bernhard Kober; Sandra Röddiger; Thomas Martin; George Fountzilas; Nikolaos Zamboglou Journal: Strahlenther Onkol Date: 2003-05 Impact factor: 3.621
Authors: Ann D King; David K W Yeung; Anil T Ahuja; S F Leung; Gary M K Tse; Andrew C van Hasselt Journal: AJNR Am J Neuroradiol Date: 2004-03 Impact factor: 3.825
Authors: S F Nemec; C R Krestan; I M Noebauer-Huhmann; M Formanek; J Frühwald; P Peloschek; F Kainberger; C Czerny Journal: Radiologe Date: 2009-01 Impact factor: 0.635
Authors: Sasan Partovi; Andres Kohan; Christian Rubbert; Jose Luis Vercher-Conejero; Chiara Gaeta; Roger Yuh; Lisa Zipp; Karin A Herrmann; Mark R Robbin; Zhenghong Lee; Raymond F Muzic; Peter Faulhaber; Pablo R Ros Journal: Am J Nucl Med Mol Imaging Date: 2014-03-20
Authors: Ilda Patrícia Ribeiro; Francisco Caramelo; Francisco Marques; Ana Domingues; Margarida Mesquita; Leonor Barroso; Hugo Prazeres; Maria José Julião; Isabel Poiares Baptista; Artur Ferreira; Joana Barbosa Melo; Isabel Marques Carreira Journal: Cell Oncol (Dordr) Date: 2016-08-04 Impact factor: 6.730
Authors: Ann D King; David K W Yeung; Kwok-Hung Yu; Frankie K F Mo; Chen-Wen Hu; Kunwar S Bhatia; Gary M K Tse; Alexander C Vlantis; Jeffrey K T Wong; Anil T Ahuja Journal: Eur Radiol Date: 2009-08-05 Impact factor: 5.315